Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
52
PRN.TO Quote, Financials, Valuation and Earnings
Last price:
$10.46
Seasonality move
:
35.08%
Day range:
$9.89 - $10.59
52-week range:
$5.23 - $11.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.20x
P/B ratio:
7.06x
Volume:
40.3K
Avg. volume:
24.5K
1-year change:
0.58%
Market cap:
$315.8M
Revenue:
$14.6M
EPS (TTM):
-$1.87
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRN.TO
Profound Medical Corp.
|
$9.8M | -$0.38 | 89.28% | -44.37% | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
GUD.TO
Knight Therapeutics, Inc.
|
$114.6M | -- | 22% | -90.68% | $7.93 |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRN.TO
Profound Medical Corp.
|
$10.46 | -- | $315.8M | -- | $0.00 | 0% | 15.20x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
GUD.TO
Knight Therapeutics, Inc.
|
$6.00 | $7.93 | $595.7M | 1,890.63x | $0.00 | 0% | 1.45x |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0250 | -- | $256.9K | 0.65x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRN.TO
Profound Medical Corp.
|
12.89% | 0.573 | 3.22% | 3.30x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
GUD.TO
Knight Therapeutics, Inc.
|
12.17% | -0.657 | 18.13% | 1.40x |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRN.TO
Profound Medical Corp.
|
$5.4M | -$12.3M | -81.8% | -91.61% | -168.52% | -$13.2M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
GUD.TO
Knight Therapeutics, Inc.
|
$40.4M | $646K | -0.41% | -0.45% | 0.53% | $7.7M |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Profound Medical Corp. vs. Competitors
-
Which has Higher Returns PRN.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of --. Profound Medical Corp.'s return on equity of -91.61% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRN.TOProfound Medical Corp.74.32% -$0.37 $51.3M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About PRN.TO or COOL.CX?
Profound Medical Corp. has a consensus price target of --, signalling upside risk potential of 105.55%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Profound Medical Corp. has higher upside potential than Core One Labs, Inc., analysts believe Profound Medical Corp. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRN.TOProfound Medical Corp.4 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is PRN.TO or COOL.CX More Risky?
Profound Medical Corp. has a beta of 0.068, which suggesting that the stock is 93.156% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock PRN.TO or COOL.CX?
Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRN.TO or COOL.CX?
Profound Medical Corp. quarterly revenues are $7.3M, which are larger than Core One Labs, Inc. quarterly revenues of --. Profound Medical Corp.'s net income of -$11M is higher than Core One Labs, Inc.'s net income of --. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.20x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRN.TOProfound Medical Corp.15.20x -- $7.3M -$11M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns PRN.TO or CURE.X.CX?
Biocure Technology has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of --. Profound Medical Corp.'s return on equity of -91.61% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRN.TOProfound Medical Corp.74.32% -$0.37 $51.3M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About PRN.TO or CURE.X.CX?
Profound Medical Corp. has a consensus price target of --, signalling upside risk potential of 105.55%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Profound Medical Corp. has higher upside potential than Biocure Technology, analysts believe Profound Medical Corp. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings PRN.TOProfound Medical Corp.4 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is PRN.TO or CURE.X.CX More Risky?
Profound Medical Corp. has a beta of 0.068, which suggesting that the stock is 93.156% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRN.TO or CURE.X.CX?
Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRN.TO or CURE.X.CX?
Profound Medical Corp. quarterly revenues are $7.3M, which are larger than Biocure Technology quarterly revenues of --. Profound Medical Corp.'s net income of -$11M is higher than Biocure Technology's net income of --. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.20x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRN.TOProfound Medical Corp.15.20x -- $7.3M -$11M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns PRN.TO or GUD.TO?
Knight Therapeutics, Inc. has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of -3.12%. Profound Medical Corp.'s return on equity of -91.61% beat Knight Therapeutics, Inc.'s return on equity of -0.45%.
Company Gross Margin Earnings Per Share Invested Capital PRN.TOProfound Medical Corp.74.32% -$0.37 $51.3M GUD.TOKnight Therapeutics, Inc.33.21% -$0.04 $873M -
What do Analysts Say About PRN.TO or GUD.TO?
Profound Medical Corp. has a consensus price target of --, signalling upside risk potential of 105.55%. On the other hand Knight Therapeutics, Inc. has an analysts' consensus of $7.93 which suggests that it could grow by 31.19%. Given that Profound Medical Corp. has higher upside potential than Knight Therapeutics, Inc., analysts believe Profound Medical Corp. is more attractive than Knight Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRN.TOProfound Medical Corp.4 0 0 GUD.TOKnight Therapeutics, Inc.2 1 0 -
Is PRN.TO or GUD.TO More Risky?
Profound Medical Corp. has a beta of 0.068, which suggesting that the stock is 93.156% less volatile than S&P 500. In comparison Knight Therapeutics, Inc. has a beta of 0.116, suggesting its less volatile than the S&P 500 by 88.421%.
-
Which is a Better Dividend Stock PRN.TO or GUD.TO?
Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Knight Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. Knight Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRN.TO or GUD.TO?
Profound Medical Corp. quarterly revenues are $7.3M, which are smaller than Knight Therapeutics, Inc. quarterly revenues of $121.5M. Profound Medical Corp.'s net income of -$11M is lower than Knight Therapeutics, Inc.'s net income of -$3.8M. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while Knight Therapeutics, Inc.'s PE ratio is 1,890.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.20x versus 1.45x for Knight Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRN.TOProfound Medical Corp.15.20x -- $7.3M -$11M GUD.TOKnight Therapeutics, Inc.1.45x 1,890.63x $121.5M -$3.8M
-
Which has Higher Returns PRN.TO or HEAL.CX?
has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of --. Profound Medical Corp.'s return on equity of -91.61% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRN.TOProfound Medical Corp.74.32% -$0.37 $51.3M HEAL.CX-- -- -- -
What do Analysts Say About PRN.TO or HEAL.CX?
Profound Medical Corp. has a consensus price target of --, signalling upside risk potential of 105.55%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Profound Medical Corp. has higher upside potential than , analysts believe Profound Medical Corp. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings PRN.TOProfound Medical Corp.4 0 0 HEAL.CX0 0 0 -
Is PRN.TO or HEAL.CX More Risky?
Profound Medical Corp. has a beta of 0.068, which suggesting that the stock is 93.156% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock PRN.TO or HEAL.CX?
Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRN.TO or HEAL.CX?
Profound Medical Corp. quarterly revenues are $7.3M, which are larger than quarterly revenues of --. Profound Medical Corp.'s net income of -$11M is higher than 's net income of --. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.20x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRN.TOProfound Medical Corp.15.20x -- $7.3M -$11M HEAL.CX-- -- -- --
-
Which has Higher Returns PRN.TO or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of -150.82% compared to Profound Medical Corp.'s net margin of --. Profound Medical Corp.'s return on equity of -91.61% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PRN.TOProfound Medical Corp.74.32% -$0.37 $51.3M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About PRN.TO or NSHS.CX?
Profound Medical Corp. has a consensus price target of --, signalling upside risk potential of 105.55%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Profound Medical Corp. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Profound Medical Corp. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRN.TOProfound Medical Corp.4 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is PRN.TO or NSHS.CX More Risky?
Profound Medical Corp. has a beta of 0.068, which suggesting that the stock is 93.156% less volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock PRN.TO or NSHS.CX?
Profound Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Profound Medical Corp. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRN.TO or NSHS.CX?
Profound Medical Corp. quarterly revenues are $7.3M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Profound Medical Corp.'s net income of -$11M is lower than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Profound Medical Corp.'s price-to-earnings ratio is -- while NanoSphere Health Sciences, Inc.'s PE ratio is 0.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Profound Medical Corp. is 15.20x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRN.TOProfound Medical Corp.15.20x -- $7.3M -$11M NSHS.CXNanoSphere Health Sciences, Inc.-- 0.65x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
